Lymphact owns the necessary international patents (PCT's) for its DOT-Cells® technology granted in the USA, Europe, Japan and China. We protected not only the new cell line of white blood cells, but also its manufacture processes, and the clinical applications it can cover (cancer and chronic viral diseases).
Oncology is amongst the fastest-growing therapeutic areas in terms of branded therapeutic revenue. In 2010, all 10 of the top 10 oncology drugs exceeded $1 billion in sales (Oncology National Commercial Study, Campbell Alliance 2010).
Our first product is an autologous cell therapy, designed to treat Leukaemia, a rare and still incurable disease. Please check our pipeline page to see our future products.